Statin use increased from 1999-2000 to 2013-2014, then plateaued
Dec 04, 2023
No change was seen in the proportion using statins from 2013-2014 to 2017-2018 for those with diabetes and with ASCVD risk greater than 20%.
EPA proposes removing 100 percent of lead pipes from US water system
Nov 30, 2023
Utility companies expected to cover most of the cost, but there is $15 billion available in the 2021 infrastructure law to help
AHA: Semaglutide cuts risk for CVD events in patients without diabetes
Nov 14, 2023
Findings seen over three years in adults with preexisting cardiovascular disease and overweight or obesity
Gender life expectancy gap increased from 2010 to 2021
Nov 13, 2023
The leading contributors to the widening gender life expectancy gap from 2019 to 2021 included COVID-19 and unintentional injuries.
AHA: PREVENT risk calculator estimates risk for cardiovascular disease
Nov 13, 2023
PREVENT equations were developed and validated in adults aged 30 to 79 years without known CVD and included eGFR as a predictor.
Extreme heat projected to cause more excess cardiovascular deaths by midcentury
Oct 30, 2023
In one scenario, elderly adults are projected to have a 3.5 times greater increase in deaths compared with nonelderly adults.
Burden of heart disease considerable for American Indians, Alaska Natives
Sep 26, 2023
Half of the participants reported at least one severe cardiovascular condition; the overall mortality rate was 19.8%.
Whites have greatest magnitude of association of socioeconomic status with LE8
Sep 13, 2023
The magnitude of the positive association for four socioeconomic status categories with LE8 was greater for non-Hispanic whites than for minority groups.
Cardiac arrest survival lower at EMS agencies serving minority populations
Sep 13, 2023
The difference was not explained by response times, rates of EMS termination of resuscitation or rates of initiating CPR or automated external defibrillator.
Heart, diabetes, cancer drugs on list for Medicare price negotiations, White House says
Aug 29, 2023
Enrollees in the Medicare prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for the 10 initial drugs chosen for price negotiations.